Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

COVID-19 Excess Deaths in Peru’s 25 States in 2020: Nationwide Trends, Confounding Factors, and Correlations With the Extent of Ivermectin Treatment by State

Chamie et al., Cureus, doi:10.7759/cureus.43168
Aug 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now known with p < 0.00000000001 from 100 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19ivm.org
Ecological analysis showing that ivermectin distribution correlated significantly (p<0.002) with the reduction in excess deaths across 25 states in Peru.
Ivermectin was authorized for COVID-19 treatment in Peru in May 2020 and distributed to varying degrees across the states. 10 states had mass ivermectin distributions through the Mega-Operación Tayta (MOT) program. Excess deaths were calculated using mortality data from Peru's national health system.
In the 10 MOT states with maximal ivermectin usage, excess deaths dropped by 74% on average 30 days after peak deaths. In 14 states with moderate ivermectin usage, deaths dropped 53%. In Lima with minimal ivermectin usage, deaths dropped 25%.
Reductions in excess deaths correlated significantly (p<0.002) with extent of ivermectin distributions across the 25 states.
After the new Peruvian president restricted ivermectin use in November 2020, nationwide excess deaths increased 13-fold over the next 2 months.
The significant correlation between ivermectin usage and reduced excess deaths held despite considering other potential confounding factors like mobility, viral strains, and seropositivity.
In summary, this ecological study found that ivermectin usage correlated with reduced COVID-19 mortality across Peru in 2020, based on data for excess deaths and ivermectin distributions across 25 states.
Chamie et al., 8 Aug 2023, placebo-controlled, Peru, peer-reviewed, 3 authors, study period 1 August, 2020 - 1 December, 2020. Contact: dscheim@alum.mit.edu.
This PaperIvermectinAll
COVID-19 Excess Deaths in Peru’s 25 States in 2020: Nationwide Trends, Confounding Factors, and Correlations With the Extent of Ivermectin Treatment by State
Juan J Chamie, Jennifer A Hibberd, David E Scheim
Cureus, doi:10.7759/cureus.43168
Introduction In 2020, nations hastened to contain an emerging COVID-19 pandemic by deploying diverse public health approaches, but conclusive appraisals of the efficacy of these approaches are elusive in most cases. One of the medicines deployed, ivermectin (IVM), a macrocyclic lactone having biochemical activity against SARS-CoV-2 through competitive binding to its spike protein, has yielded mixed results in randomized clinical trials (RCTs) for COVID-19 treatments. In Peru, an opportunity to track the efficacy of IVM with a close consideration of confounding factors was provided through data for excess deaths as correlated with IVM use in 2020, under semi-autonomous policies in its 25 states. Methods To evaluate possible IVM treatment effects, excess deaths as determined from Peruvian national health data were analyzed by state for ages ≥60 in Peru's 25 states. These data were compared with monthly summary data for excess deaths in Peru for the period 2020-2021 as published by the WHO in 2022. To identify potential confounding factors, Google mobility data, population densities, SARS-CoV-2 genetic variations, and seropositivity rates were also examined. Results Reductions in excess deaths over a period of 30 days after peak deaths averaged 74% in the 10 states with the most intensive IVM use. As determined across all 25 states, these reductions in excess deaths correlated closely with the extent of IVM use (p<0.002). During four months of IVM use in 2020, before a new president of Peru restricted its use, there was a 14-fold reduction in nationwide excess deaths and then a 13-fold increase in the two months following the restriction of IVM use. Notably, these trends in nationwide excess deaths align with WHO summary data for the same period in Peru. Conclusions The natural experiment that was put into motion with the authorization of IVM use for COVID-19 in Peru in May 2020, as analyzed using data on excess deaths by locality and by state from Peruvian national health sources, resulted in strong evidence for the drug's effectiveness. Several potential confounding factors, including effects of a social isolation mandate imposed in May 2020, variations in the genetic makeup of the SARS-CoV-2 virus, and differences in seropositivity rates and population densities across the 25 states, were considered but did not appear to have significantly influenced these outcomes.
Additional Information Disclosures Human subjects: All authors have confirmed that this study did not involve human participants or tissue.
References
Aminpour, Cannariato, Safaeeardebili, In silico analysis of the multi-targeted mode of action of ivermectin and related compounds, Computation, doi:10.3390/computation10040051
Babalola, Ndanusa, Adesuyi, Ogedengbe, Thairu et al., A randomized controlled trial of ivermectin monotherapy versus HCQ, IVM, and AZ combination therapy in Covid-19 patients in Nigeria, J Infect Dis Epidemiol, doi:10.23937/2474-3658/1510233
Badr, Du, Marshall, Dong, Squire et al., Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study, Lancet Infect Dis, doi:10.1016/S1473-3099(20)30553-3
Bermúdez, If a doctor evaluates a person and prescribes ivermectin, they can use it
Boretti, Zinc augments the antiviral potential of HCQ/CQ and ivermectin to reduce the risks of more serious outcomes from COVID-19 infection, J Trace Elem Med Biol, doi:10.1016/j.jtemb.2022.126954
Bramante, Huling, Tignanelli, Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19, N Engl J Med, doi:10.1056/NEJMoa2201662
Breakwater, IDL Reporters
Buonfrate, Chesini, Martini, High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2021.106516
Cabezas, Fiestas, García-Mendoza, Palomino, Mamani et al., Dengue in Peru: a quarter of a century after its reemergence, Revista Peruana de Medicina Experimental y Salud Publica
Campbell, History of avermectin and ivermectin, with notes on the history of other macrocyclic lactone antiparasitic agents, Curr Pharm Biotechnol, doi:10.2174/138920112800399095
Chaccour, Lines, Whitty, Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans: the potential of oral insecticides in malaria control, J Infect Dis, doi:10.1086/653208
Chahla, Ruiz, Ortega, Intensive treatment with ivermectin and iota-carrageenan as pre-exposure prophylaxis for COVID-19 in health care workers from Tucuman, Argentina, Am J Ther, doi:10.1097/MJT.0000000000001433
Chamie-Quintero, Hibberd, Scheim, Ivermectin for COVID-19 in Peru: 14-fold reduction in nationwide excess deaths, p<0.002 for effect by state, then 13-fold increase after ivermectin use restricted
Comercio, A trip to the black market of COVID-19
Crump, Ōmura, Ivermectin, wonder drug' from Japan: the human use perspective, Proc Jpn Acad Ser B Phys Biol Sci, doi:10.2183/pjab.87.13
De Castro, Jr, Gregianin, Burger, Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection, Leuk Lymphoma, doi:10.1080/10428194.2020.1786559
Desort-Henin, Kostova, Babiker, Caramel, Malamut, The SAIVE Trial, post-exposure use of ivermectin in COVID-19 prevention: efficacy and safety results
Guzzo, Furtek, Porras, Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects, J Clin Pharmacol, doi:10.1177/009127002401382731
Hazan, Gunaratne, Dolai, Clancy, Mccullough et al., Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients, Future Microbiol, doi:10.2217/fmb-2022-0014
Hibberd, Scheim, Google community mobility trends, seropositivity rates, comparisons of SINADEF data with who summary data, and other data items as useful in analysis of excess deaths during the COVID-19 pandemic in Peru
Hibberd, Scheim, Sharp reductions in COVID-19 case fatalities and excess deaths in Peru in close time conjunction, state-bystate
Ioannidis, Evidence-based medicine has been hijacked: a report to David Sackett, J Clin Epidemiol, doi:10.1016/j.jclinepi.2016.02.012
Juarez, Schcolnik-Cabrera, Dueñas-Gonzalez, The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug, Am J Cancer Res
Juscamayta-López, Carhuaricra, Tarazona, Valdivia, Rojas et al., Phylogenomics reveals multiple introductions and early spread of SARS-CoV-2 into Peru, J Med Virol, doi:10.1002/jmv.27167
Karim, Devnarain, Time to stop using ineffective COVID-19 drugs, N Engl J Med, doi:10.1056/NEJMe2209017
Kerr, Baldi, Lobo, Regular use of ivermectin as prophylaxis for COVID-19 led up to a 92% reduction in COVID-19 mortality rate in a dose-response manner: results of a prospective observational study of a strictly controlled population of 88, doi:10.7759/cureus.28624
Kory, Meduri, Varon, Iglesias, Marik, Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19, Am J Ther, doi:10.1097/MJT.0000000000001377
Krolewiecki, Lifschitz, Moragas, Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial, EClinicalMedicine, doi:10.1016/j.eclinm.2021.100959
Lehrer, Rheinstein, Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2, doi:10.21873/invivo.12134
Lim, Hor, Tay, Efficacy of ivermectin treatment on disease progression among adults with mild to moderate covid-19 and comorbidities: the I-TECH randomized clinical trial, JAMA Intern Med, doi:10.1001/jamainternmed.2022.0189
Lima, None
López-Medina, 38 switched ivermectin (IVM) and placebo doses, failure of blinding, ubiquitous IVM use OTC in Cali, and nearly identical AEs for the IVM and control groups
López-Medina, López, Hurtado, Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial, JAMA, doi:10.1001/jama.2021.3071
Naggie, Boulware, Lindsell, Effect of higher-dose ivermectin for 6 days vs placebo on time to sustained recovery in outpatients with COVID-19: a randomized clinical trial, JAMA, doi:10.1001/jama.2023.1650
Naggie, Boulware, Lindsell, Effect of ivermectin vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial, JAMA, doi:10.1001/jama.2022.18590
Navarro, Camprubí, Requena-Méndez, Safety of high-dose ivermectin: a systematic review and meta-analysis, J Antimicrob Chemother, doi:10.1093/jac/dkz524
Nicolelis, Raimundo, Peixoto, Andreazzi, The impact of super-spreader cities, highways, and intensive care availability in the early stages of the COVID-19 epidemic in Brazil, Sci Rep, doi:10.1038/s41598-021-92263-3
Nih Covid-, Fluvoxamine: selected clinical data, limitations and interpretation
Oh, Lee, Khuong, Mobility restrictions were associated with reductions in COVID-19 incidence early in the pandemic: evidence from a real-time evaluation in 34 countries, Sci Rep, doi:10.1038/s41598-021-92766-z
Padilla-Rojas, Vega-Chozo, Galarza-Perez, Genomic analysis reveals local transmission of SARS-CoV-2 in early pandemic phase in Peru, bioRxiv, doi:10.1101/2020.09.05.284604
Puno, Starting tomorrow they will implement the Tayta operation led by the Peruvian Army
Reis, Silva, Silva, Effect of early treatment with ivermectin among patients with COVID-19, N Engl J Med, doi:10.1056/NEJMoa2115869
Saltelli, Dankel, Fiore, Holland, Pigeon M: Science, the endless frontier of regulatory capture, Futures, doi:10.1016/j.futures.2021.102860
Santin, Scheim, Mccullough, Yagisawa, Borody, Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19, New Microbes New Infect, doi:10.1016/j.nmni.2021.100924
Scheim, A deadly embrace: hemagglutination mediated by SARS-COV-2 spike protein at its 22 nglycosylation sites, red blood cell surface sialoglycoproteins, and antibody, Int J Mol Sci, doi:10.3390/ijms23052558
Scheim, Aldous, Osimani, Fordham, Hoy, When characteristics of clinical trials require perprotocol as well as intention-to-treat outcomes to draw reliable conclusions: three examples, J Clin Med. 2023, doi:10.3390/jcm12113625
Seet, Quek, Ooi, Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial, Int J Infect Dis, doi:10.1016/j.ijid.2021.04.035
Sempé, Lloyd-Sherlock, Martínez, Ebrahim, Mckee et al., Estimation of all-cause excess mortality by age-specific mortality patterns for countries with incomplete vital statistics: a populationbased study of the case of Peru during the first wave of the COVID-19 pandemic, Lancet Reg Health Am, doi:10.1016/j.lana.2021.100039
Shafiee, Athar, Gargari, Jafarabady, Siahvoshi et al., Ivermectin under scrutiny: a systematic review and meta-analysis of efficacy and possible sources of controversies in COVID-19 patients, Virol J, doi:10.1186/s12985-022-01829-8
Shouman, Hegazy, Nafae, Use of ivermectin as a prophylactic option in asymptomatic family close contacts with patients of COVID-19 (NCT number: 04422561), J Clin Diagnostic Res
Stokes, Turner, Anselmi, Morciano, Hone, The relative effects of non-pharmaceutical interventions on wave one Covid-19 mortality: natural experiment in 130 countries, doi:10.1186/s12889-022-13546-6
Stone, Ndarukwa, Scheim, Changes in SpO2 on room air for 34 severe COVID-19 patients after ivermectin-based combination treatment: 62% normalization within 24 hours, Biologics, doi:10.3390/biologics2030015
Unwin, Mishra, Bradley, State-level tracking of COVID-19 in the United States, Nat Commun, doi:10.1038/s41467-020-19652-6
Vallejos, Zoni, Bangher, Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial, BMC Infect Dis, doi:10.1186/s12879-021-06348-5
Wessa, net Free Statistics Software, Office for Research Development and Education, version 1.2.1
Yagisawa, Foster, Hanaki, Omura, Global trends in clinical studies of ivermectin in COVID-19, Jpn J Antibiot
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit